The effect of the nicotinic agonist AG-4 on memory processes was evaluated in the mouse passive avoidance test. AG-4 (100 mg per mouse icv) prevented amnesia induced by scopolamine (1.5 mg kg–1 ip), mecamylamine (20 mg kg–1 ip), and dihydro-b-erythroidine (10 mg per mouse icv). In the same experimental conditions, AG-4 (100 mg per mouse icv) also prevented baclofen (2 mg kg–1 ip), clonidine (0.125 mg kg–1 ip), and diphenhydramine (20 mg kg–1 ip) amnesia in mice. AG-4 exerted an antiamnesic effect comparable to that produced by nicotine (2 mg kg–1 ip), physostigmine (0.2 mg kg–1 ip), and the nootropic drug piracetam (30 mg kg–1 ip). At the active dose, AG-4 did not impair mice motor coordination and spontaneous motility as revealed, respectively, by Rota-rod test and Animex apparatus. Present results evidence the antiamnesic activity of the nicotinic agonist AG-4 suggesting a potential employment of this compound in the symptomatic treatment of cognitive impairments.

AG-4:A NICOTINIC AGONIST ENDOWED WITH ANTIAMNESIC PROPERTIES / C. GHELARDINI; N. GALEOTTI; L. DI CESARE MANNELLI; S. DEI; F. GUALTIERI; A. BARTOLINI. - In: DRUG DEVELOPMENT RESEARCH. - ISSN 0272-4391. - STAMPA. - 51:(2000), pp. 191-196. [10.1002/1098-2299(200011)51:3<191::AID-DDR8>3.0.CO;2-K]

AG-4:A NICOTINIC AGONIST ENDOWED WITH ANTIAMNESIC PROPERTIES

GHELARDINI, CARLA;GALEOTTI, NICOLETTA;DI CESARE MANNELLI, LORENZO;DEI, SILVIA;GUALTIERI, FULVIO;BARTOLINI, ALESSANDRO
2000

Abstract

The effect of the nicotinic agonist AG-4 on memory processes was evaluated in the mouse passive avoidance test. AG-4 (100 mg per mouse icv) prevented amnesia induced by scopolamine (1.5 mg kg–1 ip), mecamylamine (20 mg kg–1 ip), and dihydro-b-erythroidine (10 mg per mouse icv). In the same experimental conditions, AG-4 (100 mg per mouse icv) also prevented baclofen (2 mg kg–1 ip), clonidine (0.125 mg kg–1 ip), and diphenhydramine (20 mg kg–1 ip) amnesia in mice. AG-4 exerted an antiamnesic effect comparable to that produced by nicotine (2 mg kg–1 ip), physostigmine (0.2 mg kg–1 ip), and the nootropic drug piracetam (30 mg kg–1 ip). At the active dose, AG-4 did not impair mice motor coordination and spontaneous motility as revealed, respectively, by Rota-rod test and Animex apparatus. Present results evidence the antiamnesic activity of the nicotinic agonist AG-4 suggesting a potential employment of this compound in the symptomatic treatment of cognitive impairments.
51
191
196
C. GHELARDINI; N. GALEOTTI; L. DI CESARE MANNELLI; S. DEI; F. GUALTIERI; A. BARTOLINI
File in questo prodotto:
File Dimensione Formato  
52.AG4 DDR 2000.pdf

accesso aperto

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Open Access
Dimensione 122.36 kB
Formato Adobe PDF
122.36 kB Adobe PDF Visualizza/Apri

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/307732
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact